Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sargramostim (GM-CSF)

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Sargramostim (GM-CSF). Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-006140-20 Sponsor Protocol Number: 005/05 Start Date*: 2009-06-01
    Sponsor Name:BioVex Inc
    Full Title: A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage ...
    Medical condition: Unresectable Stage IIIb, IIIc and IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021070-11 Sponsor Protocol Number: 005/05E Start Date*: 2010-11-23
    Sponsor Name:BioVex Inc
    Full Title: An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEX GM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
    Medical condition: Unresectable Stage IIIb, IIIc and IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007086-23 Sponsor Protocol Number: FARM7MCPK4 Start Date*: 2008-12-12
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis.
    Medical condition: Autoimmune PAP
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037316 Pulmonary alveolar proteinosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001829-40 Sponsor Protocol Number: 201 Start Date*: 2019-01-02
    Sponsor Name:Y-mAbs Therapeutics A/S
    Full Title: A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete...
    Medical condition: Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005815-10 Sponsor Protocol Number: AJSEB001 Start Date*: 2012-05-31
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Developmental Clinical Sciences: Does GM-CSF restore effective neutrophil function in critically ill patients?
    Medical condition: Complement mediated dysfunctional neutrophil phagocytosis in critical illness.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10061314 Neutrophil function disorder PT
    16.1 10005329 - Blood and lymphatic system disorders 10017500 Functional disorders of polymorphonuclear neutrophils LLT
    14.1 10022891 - Investigations 10061867 Neutrophil function test abnormal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006068-32 Sponsor Protocol Number: CDX110-04 Start Date*: 2012-07-04
    Sponsor Name:Celldex Therapeutics, Inc
    Full Title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma ...
    Medical condition: Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003925-17 Sponsor Protocol Number: HCC-PBMC-GM-CSF Start Date*: 2008-10-20
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation
    Medical condition: patients with hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059319 Hepatic cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004864-69 Sponsor Protocol Number: HSJD-HR-NB-Ch14.18 Start Date*: 2014-05-21
    Sponsor Name:Fundació Sant Joan de Deu de Barcelona
    Full Title: Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma...
    Medical condition: High-risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007056-33 Sponsor Protocol Number: FL2008 RCHOPGM Start Date*: 2008-09-19
    Sponsor Name:Goelams
    Full Title: An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) ...
    Medical condition: This study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) and chemotherapy (CHOP) in patients with non bulky follicular non Hodgkin...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025310 Lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005580-95 Sponsor Protocol Number: FL2008 RGM Start Date*: 2008-09-19
    Sponsor Name:Goelams
    Full Title: An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follic...
    Medical condition: This study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with non bulky follicular non Hodgkin’s lymphoma with no prio...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025310 Lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003111-31 Sponsor Protocol Number: 2007-1-18-20-6 Start Date*: 2008-07-21
    Sponsor Name:Charité - Universitaetsmedizin Berlin
    Full Title: Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative ...
    Medical condition: Post-operative immunological stimulation in severe immune suppression. The study population is made up of adult, which are able to give their inform consent by their own. The patients are undergoin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001894-15 Sponsor Protocol Number: 2014-856 Start Date*: 2015-01-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Administration de GRanulocyte–Macrophage Colony-stimulating Factor (GM-CSF) pour diminuer les Infections acquises en réanimation au cours de l’immunoDépression induite par le sepsis.Etude multicen...
    Medical condition: sepsis sévère ou choc septique dans les 24 premières heures de présence en réanimation
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003186-28 Sponsor Protocol Number: BPC01_002 Start Date*: 2016-01-13
    Sponsor Name:Bionor Pharma ASA
    Full Title: BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the H...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004747-23 Sponsor Protocol Number: BPC01-001 Start Date*: 2014-01-17
    Sponsor Name:Bionor Pharma ASA
    Full Title: An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologic...
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002272-14 Sponsor Protocol Number: CDX110-07 Start Date*: 2013-01-11
    Sponsor Name:CELLDEX THERAPEUTICS
    Full Title: An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glio...
    Medical condition: Newly diagnosed, surgically resected, EGFRvIII-positive Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021196-85 Sponsor Protocol Number: BNIT-PRV-301 Start Date*: 2012-05-04
    Sponsor Name:Bavarian Nordic, Inc.
    Full Title: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
    Medical condition: Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) EE (Prematurely Ended) IS (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002281-12 Sponsor Protocol Number: CT-BI-Vacc-4x-2012/1 Start Date*: 2013-02-01
    Sponsor Name:Bionor Immuno AS
    Full Title: Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have...
    Medical condition: Subjects Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000461-10 Sponsor Protocol Number: ISRCTN43482138 Start Date*: 2006-08-25
    Sponsor Name:The Royal Liverpool University Hospital NHS Trust
    Full Title: A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a tel...
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009863-75 Sponsor Protocol Number: CEAEP_2009-05-29 Start Date*: 2009-08-26
    Sponsor Name:Karolinska Institutet/ Hospital
    Full Title: El-porCEA: Assessment of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer.
    Medical condition: Colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004481-34 Sponsor Protocol Number: Uni-Koeln-1694 Start Date*: 2015-03-12
    Sponsor Name:University of Cologne
    Full Title: RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL...
    Medical condition: Recurrent, progressive or newly diagnosed high risk neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:02:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA